The Biopharmaceutical company focused on the biology of healing on Wednesday gave an extended presentation at its Annual and Special meeting of shareholders. The key messages were the variety of angles from which its products are progressing towards the market place, and the infrastructure foundations being laid so that once approvals are received, the company will be able to quickly flick the manufacturing switch to meet the demand to treat largely previously unmet clinical needs.
